Search

Your search keyword '"Shigella Vaccines"' showing total 254 results

Search Constraints

Start Over You searched for: Descriptor "Shigella Vaccines" Remove constraint Descriptor: "Shigella Vaccines"
254 results on '"Shigella Vaccines"'

Search Results

1. The identification of novel immunogenic antigens as potential Shigella vaccine components.

2. Promising directions for vaccine development to prevent shigellosis

3. Investigators at GlaxoSmithKline plc Report Findings in Shigella Vaccines (Safety and Immunogenicity of a 4-component Generalized Modules for Membrane Antigens Shigella Vaccine In Healthy European Adults: Randomized, Phase 1/2 Study).

4. Vaccines for enteric diseases

5. Reports from PATH Provide New Insights into Enterotoxigenic Escherichia coli [The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia Coli (Vase) Conference: Summary of Breakout Workshops].

6. Findings on Shigella Vaccines Reported by Investigators at Bill and Melinda Gates Foundation [Optimizing Vaccine Trials for Enteric Diseases: the Enterics for Global Health (Efgh) Shigella Surveillance Study].

7. Recent Research from University of Washington Highlight Findings in Shigella Vaccines (Diarrhea Case Surveillance In the Enterics for Global Health Shigella Surveillance Study: Epidemiologic Methods).

8. Studies Conducted at PATH on Shigella Vaccines Recently Reported (Reassessing Potential Economic Value and Health Impact of Effective shigella Vaccines).

9. Researcher from University of Missouri Discusses Findings in Shigella Vaccines (Shigella Vaccines: The Continuing Unmet Challenge).

10. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.

11. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentations.

12. B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3.

13. Reassessing potential economic value and health impact of effective Shigella vaccines.

14. The L-DBF vaccine cross protects mice against different Shigella serotypes after prior exposure to the pathogen.

15. Refining Immunogenicity through Intradermal Delivery of Outer Membrane Vesicles against Shigella flexneri in Mice.

16. A broadly immunogenic polyvalent Shigella multiepitope fusion antigen protein protects against Shigella sonnei and Shigella flexneri lethal pulmonary challenges in mice.

17. Vaccine value profile for Shigella.

18. Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries.

19. Further characterization of Shigella -specific (memory) B cells induced in healthy volunteer recipients of SF2a-TT15, a Shigella flexneri 2a synthetic glycan-based vaccine candidate.

20. PATH Researchers Publish New Studies and Findings in the Area of Shigella Vaccines (Exploring Shigella vaccine priorities and preferences: Results from a mixed-methods study in low- and middle-income settings).

21. Studies from University of Nevada Reveal New Findings on Shigella Vaccines (Challenges and Opportunities In Developing a Shigella-containing Combination Vaccine for Children In Low- and Middle-income Countries: Report of an Expert Convening).

22. New Shigella Vaccines Study Findings Recently Were Reported by Researchers at University of Illinois (A Broadly Immunogenic Polyvalent shigella Multiepitope Fusion Antigen Protein Protects Against shigella Sonnei and shigella...).

23. Characterization of Functional B-Cell Epitopes at the Amino Terminus of Shigella Invasion Plasmid Antigen B (IpaB)

24. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study

25. Immunization of Rabbits with a Quadrivalent

26. Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (Invaplex AR ) vaccines.

27. Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.

28. Oral Administration of a

29. Development of a Self-Adjuvanting, Cross-Protective, Stable Intranasal Recombinant Vaccine for Shigellosis

30. Critical needs in advancing Shigella vaccines for global health

31. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes

32. A Novel Shigella O-Polysaccharide-IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes.

33. A tetravalent Shigella outer membrane vesicles based candidate vaccine offered cross-protection against all the serogroups of Shigella in adult mice.

34. Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening.

35. Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children

36. Outer Membrane Vesicles Derived from

37. Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints

38. IpaD-loaded N-trimethyl Chitosan Nanoparticles Can Efficiently Protect Guinea Pigs against Shigella Flexneri

39. Functional antibodies as immunological endpoints to evaluate protective immunity againstShigella

40. Clinical endpoints for efficacy studies

41. Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach

42. Vaccines for enteric diseases

43. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model

44. Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection

45. Repertoire of naturally acquired maternal antibodies transferred to infants for protection against shigellosis

46. Glycoconjugation of Shigella flexneri type 2a O-polysaccharide with CRM

47. Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection

48. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.

49. Toward a Shigella Vaccine: Opportunities and Challenges to Fight an Antimicrobial-Resistant Pathogen.

50. Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding

Catalog

Books, media, physical & digital resources